The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis

A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis

February 27, 2020 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Introduction & Objectives
Interstitial lung disease (ILD) accompanied by anti-melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) is often rapidly progressive and associated with poor prognosis. A standard treatment has not yet been established. The 6-month survival rate of patients undergoing conventional treatment with glucocorticoids (GC) alone or a combination of GC and additional various immunosuppressants (step-up therapy) is 28–66% in Asian patients. Failure of these treatments seems to be partly related to rapid progression in alveolar damage before achieving sufficient immunosuppression.

You Might Also Like
  • Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap
  • Treatment Tips for Pulmonary Arterial Hypertension & ILD
  • Listen to the Lungs: An Interview with Dr. Aryeh Fischer on ILD

Recently, some case reports have suggested a combined immunosuppressive therapy may be efficacious. Thus, in a single-arm study, these researchers prospectively evaluated the efficacy and safety of a combined immunosuppressive regimen for anti-MDA5-positive DM with ILD.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Methods
Adult Japanese patients with newly onset anti-MDA5-positive DM with ILD (n=29) were enrolled in multiple centers from 2014 to 2017. They were treated with a regimen of high-dose glucocorticoids (GC), tacrolimus and intravenous cyclophosphamide (IVCY). Plasmapheresis (i.e., plasma was removed, then replaced with an equivalent amount of fresh frozen plasma or 5% albumin) was used if patients worsened after the regimen started. The primary endpoint was six-month survival, compared with that of a historical control (n=15) of patients with anti-MDA5-positive DM with ILD who received step-up treatment (high-dose GC and stepwise addition of immunosuppressant). Secondary endpoints were 12-month survival rate, adverse events and changes in laboratory data.

Two patients dropped out of the treatment regimen because their treatment differed from that of the prescribed regimen during the observation period: Administration of IVCY was considerably delayed for one patient, and IVCY was changed to infliximab for the other patient.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results
The combined immunosuppressive regimen group showed significantly higher 6-month survival than the step-up treatment group (89% and 33%, respectively, P<0.0001). In the combined immunosuppressive group, 23 of 27 patients survived. In the step-up treatment group, 10 of 15 patients died.

Over 52 weeks, anti-MDA5 titer, serum ferritin level, percent vital capacity and chest high-resolution computed tomography scores improved. The combined immunosuppressive regimen group received IVCY nearly 20 days earlier with shorter intervals and tended to receive plasmapheresis more often than patients undergoing step-up treatment (n=15). Cytomegalovirus reactivation was frequently observed over 52 weeks.

All survivors recovered to a state in which oxygenation was not required. All deaths were due to exacerbation of ILD; however, infections seemed to trigger the exacerbation.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Conclusion
A combined immunosuppressive regimen is effective for anti-MDA5-positive DM with ILD. Plasmapheresis can be used for additional effect in intractable disease. Opportunistic infections should be carefully monitored during treatment.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Arthritis & Rheumatology, dermatomyositis (DM), ILD, interstitial lung disease (ILD)

You Might Also Like:
  • Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap
  • Treatment Tips for Pulmonary Arterial Hypertension & ILD
  • Listen to the Lungs: An Interview with Dr. Aryeh Fischer on ILD
  • What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.